Researchers at the University of Manchester have made a breakthrough in developing a new class of cancer drugs that target the Aurora B enzyme, which helps cells divide and can lead to uncontrolled cell growth in cancer. Early clinical trials suggest the drug's toxicity is mild, offering a revolutionary new way to treat cancer.
A team of researchers identified a protein, Lck, that plays a crucial role in stimulating immune cells to recall past encounters with pathogens, enabling quick responses to reinfection. This discovery may aid in the development of vaccines against diseases like AIDS and autoimmune disorders.
A study found that grape seed extract significantly inhibits the growth of colorectal tumors in both human cells and mice. The extract works by increasing the availability of a critical protein called Cip1/p21, which freezes the cell cycle and often pushes cancer cells to self-destruct.
Researchers at VCU University have identified a new therapeutic target for asthma, allergies, and cancer by uncovering the transport mechanism of bioactive molecule S1P out of mast cells. The study may lead to the development of new treatments for these conditions.
Cells use a molecular signature to distinguish their own RNA from viral RNA, triggering an immune response and cell suicide. This discovery opens up new possibilities for therapy, including using triphosphate-end RNAs to trigger anti-viral responses and gene therapy.
Researchers at Mayo Clinic have discovered a protein pair that could be used to prevent tumors. The study found that CDK2 modifies FOXO1 in damaged cells, triggering apoptosis and potentially halting cancer cell growth. This breakthrough provides new hope for the development of targeted anti-tumor therapies.
A new technique called multi-isotope imaging mass spectrometry (MIMS) allows researchers to image and quantify molecules at a subcellular level. This enables the tracking of individual donor cells after transplantation and the measurement of cancer treatment drug efficacy within cells.
Researchers at the University of Illinois Chicago have identified an antibiotic that specifically targets the FoxM1 gene, which is responsible for cancer cell proliferation. The antibiotic, siomycin A, was found to induce cancer cells to commit suicide in a process called apoptosis, with no effect on normal cells.
Researchers have unveiled a new systematic approach to drug discovery that matches diseases with potential treatments using gene signatures. The 'Human Connectivity Map' allows scientists to compare disease signatures with those of treated cells, identifying effective treatments for cancer, obesity and Alzheimer's disease.
The University of Virginia School of Medicine has received a $35.7 million grant renewal from the National Institute of General Medical Sciences to continue its Cell Migration Consortium research. The consortium, comprising nearly 40 researchers globally, aims to understand cell migration and its role in diseases like cancer.
Researchers at Mayo Clinic found that the protein p120 catenin can both suppress and promote metastasis, depending on its interaction with cadherin proteins. The study suggests that a future designer drug could block the beginning of metastasis or stop it once it starts.
Researchers at The Wistar Institute have determined the three-dimensional structure of a key two-molecule complex involved in long-term gene storage, primarily in non-growing cells. This discovery provides important insights into how cells protect genes that could trigger cancers and other disorders.
Newly discovered behavior in cancer cells reveals a toggle switch that enables them to morph into highly mobile cells, invade other tissues, and adapt comfortably. This understanding could lead to finding ways to stop metastasis, the most deadly trait of cancer.
Researchers discovered that viruses can infect cells more efficiently by attaching to different carbohydrates on the cell surface. This finding helps explain how flu and other viruses evade the immune system and may be useful for developing gene therapies for cancer and brain diseases.
Researchers successfully exploited oxidative stress in cancer cells to preferentially kill malignant cells while exhibiting minimal toxicity in normal cells. The study found that a naturally occurring compound called PEITC can be used to achieve such activity.
Researchers at Salk Institute discover that cancer cells use NF-kB survival factor to stay alive when attacked by chemotherapeutic drugs. This finding suggests a strategy to enhance the effectiveness of rapamycin-based therapies by inhibiting NF-kB signaling.
A Purdue University researcher has shed light on the details of one mechanism by which targeted drug therapy is achieved. The understanding of how to deliver and unload a cancer drug can be extrapolated to other diseased cells, including those involved in arthritis, multiple sclerosis, and Crohn's disease.
Scientists have found a way to get purine nucleoside phosphorylase (PNP) into the cells of mice lacking the enzyme, which could lead to a treatment for individuals with PNP deficiency. The PTD-PNP fusion protein corrected most immune defects in Pnp-deficient mice.
Researchers at the University of Illinois Chicago discovered a molecular motor that helps cells determine which way is up by transporting a key lipid. This process is essential for maintaining cell polarity and preventing cancerous metastasis. The study sheds light on the trafficking and disposition of polarity determinants.
Researchers identify small synthetic molecule PAC-1 that directly activates procaspase-3 and induces apoptosis in cancer cells. This discovery offers a promising approach for personalized anti-cancer therapy by bypassing the broken signaling pathway in cancer cells.
Human cells exposed to high-energy protons and then iron or titanium particles showed a significant increase in anchorage-independent growth, a characteristic of early cancer development. The timing of the particle exposure was critical, with cells responding more strongly when hit by protons first.
Researchers have developed a method to synthesize rasfonin, a cancer-killing compound derived from a fungus, in enough quantity to conduct proper biological tests. The new process produces 67 times more rasfonin than previous methods, offering a promising lead for the development of a potential anticancer drug.
A new study suggests that post-transplant lymphoproliferative disorder (PTLD) arises when immune cells called scout cells become weakened, allowing the Epstein-Barr virus to cause cancer. The study identifies a mechanism that may explain why some patients develop PTLD and others don't.
Researchers investigated nutritional links between smoking and oral cancer, finding folate levels lower in smokers' blood and cheek cells. Smokers also had altered forms of folate distribution, while antioxidants like carotenoids and vitamin E showed similar trends. More studies are needed to clarify these findings.
Researchers at the Ludwig Institute for Cancer Research discovered that SREBP1 regulates both lipid synthesis and cell cycle progression. Disrupting SREBP1 activity can prevent lipid production, which is essential for new cell wall construction.
Researchers at the Mayo Clinic have engineered a modified measles virus that specifically targets and kills cancer cells by recognizing unique protein secretions. This breakthrough enhances the safety and effectiveness of oncolytic virotherapy, reducing the risk of unintended infections while improving cancer treatment outcomes.
Researchers at the University of Florida have successfully tested a new method to detect leukemia cells and believe it can be used to diagnose cancer at the molecular level. The technique uses aptamers, short strands of DNA that can recognize cancerous cells without prior knowledge of molecular changes associated with the disease.
Prostate cancer cells resist hormone treatment by activating three survival strategies involving the protein BAD. The discovery may lead to new treatments or ways to monitor treatment's intended effect, such as developing a drug to prevent BAD inhibition.
Scientists at Johns Hopkins believe that heat therapy can selectively target and kill cancer cells by disrupting their nuclear protein scaffolding. Preliminary research suggests that this approach could be effective in treating solid tumors, with the goal of improving cure rates.
MDM2 overproduced leads to unbalanced p53 regulation, promoting cancer cell growth. The study identifies protein fragments binding to MDM2, inhibiting its destructive effect on p53.
Using mass spectrometry, researchers identified three activating mutations of the tyrosine kinase JAK3 in AML cells, leading to a potential new treatment target. The study's fast and affordable approach could help analyze cancer cells for mutations in just weeks.
Researchers developed a new strategy to identify genetic mutations that drive cancerous growth by analyzing proteins instead of genes. This approach allows for rapid identification of molecular abnormalities vulnerable to specific drug treatments, enabling personalized medicine and potential targeted therapies.
Researchers at Johns Hopkins have discovered protein machinery essential for maintaining chromosome integrity in cells. Removing sirtuin proteins causes yeast cells to become hypersensitive to chemical agents and spontaneously break chromosomes.
Researchers at the University of Minnesota discover a protein's unexpected role in chopping up damaged DNA molecules, leading to cell death. The finding sheds new light on the process of apoptosis and its potential applications in cancer treatment.
Researchers found that pomegranate juice reduced PSA levels by 30% in patients with recurrent prostate cancer, slowing the doubling time of PSA levels. The antioxidant ellagic acid in pomegranate juice was also shown to increase nitric oxide production and induce programmed cell death.
Xiaodong Wang's groundbreaking discoveries in programmed cell death have provided new directions for cancer treatment, highlighting the balance between cell birth and death. His work has also revealed key proteins like cytochrome c involved in apoptosis.
Researchers at Purdue University have developed a microfluidic device that uses electricity to break down cell membranes, enabling the delivery of drugs and genes. This technique allows for detailed analysis of individual cells and can pinpoint abnormalities more quickly than traditional methods.
The study found that DNA repair pathways work at different times during cell development, with homologous recombination active in the first half and non-homologous end joining taking over later. This timing is crucial for the development of various types of cancers.
Researchers found that epigenetic treatment can induce microRNA-127, which downregulates the proto-oncogene BCL6. This may have an anticancer effect. Further studies are necessary to understand the regulation of miRNA expression in cancer.
A phase 2 trial confirms the antitumor efficacy of sunitinib in patients with metastatic clear-cell RCC refractory to cytokine therapy. Sunitinib achieved a 34% partial response rate and median progression-free survival of 8.3 months.
Researchers found that calpain promotes programmed cell death after cells are damaged, but also inhibits it in response to chemotherapeutic drugs. This discovery suggests that calpain inhibitors could improve the effectiveness of chemotherapy and radiation treatment in cancer patients.
A Phase 3 trial shows Xcytrin significantly prolongs time to neurologic progression in patients with non-small cell lung cancer and brain metastases. Xcytrin, a texaphyrin-based drug, enhances cancer cell death when combined with radiation.
A new approach to improving cancer chemotherapy involves giving anticancer drugs basic properties, allowing them to accumulate in both normal and malignant cells. This approach may lead to more effective treatment with fewer side effects.
A new compound created from vitamin E has been shown to be a potent cancer killer by blocking the Bcl-xL protein and causing programmed cell death in cancer cells. The substance kills cancer cells without damaging healthy cells, offering new hope for cancer prevention and treatment.
Dendritic cells are specialized white blood cells that patrol the body for infections. The new discovery reveals they have a highly organized structure, acting as specialized squads to deal with specific problems. This breakthrough sheds light on their role in preventing autoimmune diseases and could lead to new immune therapies.
Researchers at Ohio State University found that RHA regulates the production of growth-proteins, many of which play a role in cancer, and helps viruses establish infections. The study identifies additional genes that require RHA for translation, shedding light on cell regulation and viral mechanisms.
Researchers have developed a new technique called biochemical suppression to identify protein targets for small molecule inhibitors. This method allows for rapid identification of multiple components of complex biological systems, such as cancer cell spread.
A new cell surface profiling technique developed by Carolyn Bertozzi and her team could lead to the creation of a simple blood test for cancer diagnosis. The method involves tagging glycoproteins with a metabolic label and monitoring changes in O-linked protein glycosylation.
The Society of Nuclear Medicine and Molecular Imaging (SNM) has released a landmark procedure guideline for tumor imaging with 18F-FDG PET/CT. The document provides recommendations for patient preparation, image acquisition, interpretation criteria, and quality control to ensure high-quality imaging results.
Researchers propose a new model of p53 regulation that suggests a novel anticancer strategy using Mdm2 and Mdm4. The study reveals that Mdm4 renders p53 inactive, while Mdm2 mainly controls the stability of p53's structure.
Dr. Varshavsky's pioneering studies revealed ubiquitin's diverse roles in cell cycle, DNA repair, and responses to stress, advancing the field of molecular genetics. The March of Dimes Prize acknowledges his significant contributions to understanding birth defects, neurodegenerative syndromes, cancer, and immune disorders.
Researchers at MIT and Brigham have developed a way to design nanoparticles that can selectively deliver chemotherapy to cancer cells while leaving healthy cells intact. The particles, which are about 150 nanometers in size, use targeting molecules called aptamers to home in on cancer cells.
Researchers found that ginger causes both apoptosis and autophagic cell death in ovarian cancer cells, potentially circumventing resistance to conventional chemotherapy. The study suggests ginger may be a promising new treatment option for ovarian cancer with minimal side effects.
Researchers found that omega-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) inhibited the growth of liver cancer cells, whereas omega-6 fatty acid arachidonic acid (AA) had no effect. The compounds induced apoptosis and decreased beta-catenin levels, which are involved in tumor progression.
Scientists have engineered tiny silica particles to carry pharmaceuticals into cells using biocompatible materials and controlled release mechanisms. The mesoporous nanospheres can selectively target cancer cells by releasing drugs in response to specific chemicals, reducing side effects and increasing treatment efficacy.
Scientists have developed a method to track and quantify the absorption of multi-walled carbon nanotubes into living cells. Research found that 74% of nanotubes were assimilated by cancer cells after 15 minutes, with nearly irreversible uptake.
Scientists at the University of California, Santa Barbara, have created a new lipid molecule that delivers therapeutic genes directly to cells, potentially helping inherited diseases and cancers. The novel molecule has a tree-shaped headgroup and displays superior DNA-delivery properties.
Using computer simulations, researchers found that linked and unlinked DNA loops can be identified by their touching points. This discovery has implications for designing new drugs to treat cancer and infectious diseases.
A newly identified cell, dubbed IKDC, has been found to fight cancer by combining the abilities of natural killer (NK) and dendritic cells. This hybrid cell speeds up immune reactions and makes the system more efficient.
A cancer researcher is working on a targeted way to deliver drugs to specific cells, making treatment more precise and effective. The approach uses natural biomolecules to target diseased cells while leaving healthy ones alone.